- Home
- GERN vs GYRE Comparison
GERN vs GYRE Comparison
Compare GERN & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- GYRE
- Stock Information
- Founded
- GERN 1990
- GYRE 2002
- Country
- GERN United States
- GYRE United States
- Employees
- GERN N/A
- GYRE N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- GERN Health Care
- GYRE Health Care
- Exchange
- GERN Nasdaq
- GYRE Nasdaq
- Market Cap
- GERN 823.0M
- GYRE 755.7M
- IPO Year
- GERN 1996
- GYRE N/A
- Fundamental
- Price
- GERN $1.24
- GYRE $8.19
- Analyst Decision
- GERN Buy
- GYRE Strong Buy
- Analyst Count
- GERN 7
- GYRE 2
- Target Price
- GERN $3.17
- GYRE $17.00
- AVG Volume (30 Days)
- GERN 7.6M
- GYRE 90.0K
- Earning Date
- GERN 11-06-2025
- GYRE 11-12-2025
- Dividend Yield
- GERN N/A
- GYRE N/A
- EPS Growth
- GERN N/A
- GYRE N/A
- EPS
- GERN N/A
- GYRE 0.02
- Revenue
- GERN $164,447,000.00
- GYRE $102,189,000.00
- Revenue This Year
- GERN $172.62
- GYRE $15.25
- Revenue Next Year
- GERN $56.87
- GYRE $33.14
- P/E Ratio
- GERN N/A
- GYRE $178.16
- Revenue Growth
- GERN 11877.20
- GYRE N/A
- 52 Week Low
- GERN $1.09
- GYRE $6.11
- 52 Week High
- GERN $4.50
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- GERN 43.70
- GYRE 54.03
- Support Level
- GERN $1.19
- GYRE $7.75
- Resistance Level
- GERN $1.31
- GYRE $8.44
- Average True Range (ATR)
- GERN 0.07
- GYRE 0.41
- MACD
- GERN -0.01
- GYRE 0.02
- Stochastic Oscillator
- GERN 17.31
- GYRE 44.17
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.